Aktienanalyse zu Transcat Inc (TRNS)TRNSTranscat Inc

Transcat, Inc. is a provider of accredited calibration, reliability, maintenance optimization, quality and compliance, validation, Computerized Maintenance Management System (CMMS), and pipette services. It is focused on providing services and products to highly regulated industries, particularly the life science industry, which includes pharmaceuticals, biotechnology, medical devices, as well as aerospace and defense, and energy and utilities. It provides periodic onsite services, mobile calibration services, pickup and delivery, and in-house services at Calibration Service Centers strategically located across the United States, Puerto Rico, Canada, and Ireland. Its segments include Service and Distribution. The Service segment offers calibration, repair, inspection, analytical qualifications, preventative maintenance, consulting and other related services. The Distribution segment sells and rents national and proprietary branded instruments to customers globally. It operates in the Industrials sector (INSTRUMENTS FOR MEAS & TESTING OF ELECTRICITY & EL industry).

Transcat Inc is currently not a strong buy due to its recent price drop and mixed financial indicators. The current price is $85.85, which is below the analyst price target of $95, indicating potential upside. However, the RSI is at 29.77, suggesting the stock is oversold, and the forward P/E ratio is high at 51.02, indicating that the stock may be overvalued at this time. The main risk is the recent negative earnings trend, with a net income drop to -1.1 million in Q3 2026, which raises concerns about future profitability.

2 analysts cover TRNS: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 100.00.